Cellular dielectric spectroscopy (CDS) is an emerging technology capable of detecting a range of whole-cell responses in a label-free manner. A new CDS-based instrument, CellKey, has been developed that is optimized for G-protein coupled receptor (GPCR) detection and has automated liquid handling in microplate format, thereby making CDS accessible to lead generation/optimization drug discovery. In addition to having sufficient throughput, new assay technologies must pass rigorous standards for assay development, signal window, dynamic range, and reproducibility to effectively support drug discovery SAR studies. Here, the authors evaluated CellKey with 3 different G i -coupled GPCRs for suitability in supporting SAR studies. Optimized assay conditions compatible with the precision, reproducibility, and throughput required for routine screening were quickly achieved for each target. Across a 1000-fold range in compound potencies, CellKey results correlated with agonist and antagonist data obtained using classical methods ([ 35 S]GTPγS binding and cAMP production). For partial agonists, relative efficacy measurements also correlated with GTPγS data. CellKey detection of positive allosteric modulators appeared superior to GTPγS methodology. Agonist and antagonist activity could be accurately quantified under conditions of low receptor expression. CellKey is a new technology platform that uses label-free detection in a homogeneous assay that is unaffected by color quenching and is easily integrated into existing microtiter-based compound testing and data analysis procedures for drug discovery. (Journal of Biomolecular Screening 2007:312-319) 
INTRODUCTION
C ELLULAR DIELECTRIC SPECTROSCOPY (CDS) is an emerging technology that measures whole-cell responses in a labelfree format. The technology is based on applying electrical current to cells within a microplate format and measuring changes in impedance. 1, 2 New CDS-based instrument platforms have been developed that show promise quantifying responses as diverse as cell adhesion, proliferation, cytotoxicity, G-protein coupled receptor (GPCR) activation, and protein tyrosine kinase receptor activation. 1, [3] [4] [5] [6] For GPCRs, CDS assays offer several potential advantages that are substantial improvements over existing technologies. CDS is applicable to each of the 3 major G-protein coupled pathways. CDS is also highly versatile with respect to assay conditions. It is label free for both ligand and receptor and has minimal assay-specific cell line requirements. Finally, the sensitivity of the CDS instrument is sufficient to detect responses even with low receptor levels, including endogenous receptors. These potential advantages make it worthwhile to evaluate CDS in a drug discovery setting.
Among the 3 GPCR subtypes, application of CDS to G icoupled GPCRs (G i PCRs) is particularly noteworthy for the benefits over the currently used [ 35 S]GTPγS binding or modulation of cAMP production. [ 35 S]GTPγS binding requires radioactivity (with associated safety and disposal costs) and uses isolated plasma membrane fragments. cAMP production is a viable whole-cell assay alternative but can suffer from marginal precision due to the need to first stimulate adenylate cyclase with forskolin and then measure a reduction in this response by G i PCR agonist test compounds. The assay variability is exacerbated for G i PCR antagonists, where cyclase assays involve antagonist reversal of the agonist inhibition of forskolin response and thus require the deconvolution of the effects for 3 compounds. In contrast, CDS offers a direct measure of G i PCR activation.
The goal of this study was to assess the CellKey system (MDS Sciex, South San Francisco, CA) for utility within a drug discovery environment with a particular focus on "secondary screening" (i.e., testing newly synthesized compounds as part of the design/make/test cycle). We evaluated 3 G i PCRs for assay feasibility and development time. Data were judged for intra-and interexperiment precision and compared with data from existing assays to determine if the structure-activity relationship (SAR) could be reproduced. Agonist and antagonist assay formats were tested with compounds spanning a sufficient range in potencies and efficacy values to evaluate CellKey for the dynamic range necessary to support SAR studies. In addition to these core requirements, we also evaluated CellKey for the ability to quantify potency and cooperativity of positive allosteric modulators and for the sensitivity to characterize agonists and antagonists under conditions of low receptor expression.
MATERIALS AND METHODS

Compounds
Acetylcholine, thiochrome, brucine oxide, dopamine HCl, pergolide, bromocryptine methanesulfonate salt, S(-)-3-PPP, and 7-OH DPAT were obtained from Sigma (St. Louis, MO). Aripiprazole and AZ compounds were from AstraZeneca (Macclesfield, UK) chemistry labs. Compound stocks and serial dilutions were routinely prepared in 100% DMSO. Thiochrome and brucine-N-oxide were prepared in Hank's balanced salt solution containing 20 mM HEPES, pH 7.4 (HHBS). Dopamine HCl and S(-)-3-PPP were prepared as stocks in dH 2 0. 7-OH DPAT stock solution was prepared in 50% DMSO.
Cell culture
Human receptor cDNA was transfected into Chinese hamster ovary (CHO)-K1 cells using lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's recommendations, and stable clones were isolated using selection medium containing G418-sulfate or hygromycin. In addition to the parental CHO cells, 3 clonal cell lines stably expressing human recombinant receptors were used: (1) expressing the dopamine D 2 receptor short form (D 2S ) (13 pmol/mg protein), (2) expressing a human receptor arbitrarily called G i PCR X (8.9 pmol/mg protein), and (3) muscarinic M4 receptor (0.2 pmol/mg protein), acquired from the National Institutes of Health (NIH, Bethesda, MD). Cells were grown in Ham's F-12 media containing 10% fetal bovine serum (FBS), 700 µg/mL G418-sulfate (G i PCR X and M4) or 500 µg/mL hygromycin (D 2S clone), and 2 mM L-glutamine. Unless noted, cell culture reagents were from MediaTech (Herndon, VA). G i PCR X and M4 cells were harvested in Cellstripper™, centrifuged at 1000 rpm for 5 min, counted, and resuspended in plating media. D 2S cells were harvested, counted, and diluted in growth medium without pelleting. G i PCR X and M4 cells were seeded in 96-well CellKey plates at a density of 65,000 cells/well (50,000 cells/well for D 2S cells). To reduce edge effects for G i PCR X and M4 receptors, plates were incubated at room temperature for 20 min postplating before culturing overnight at 37 °C.
CellKey assays
Drug plates at 10× final concentration were prepared by mixing 2 µL from a DMSO stock plate with 198 µL Hank's balanced salt solution containing 20 mM HEPES, pH 7.4 (HHBS). Cell plates were washed 3 times with 135 µL in HHBS and allowed to equilibrate at 28 °C for 20 or 30 min, depending on the cell line used. Initially (for data shown in Figures 1 and 2 only) , washing and equilibration were done online in the CellKey. For all other experiments, to increase throughput, washing was done on a BioTec ELx405 SelectCW plate washer. If antagonist addition were required, this was done in the CellKey immediately following washing. Cells were then equilibrated in a 28 °C incubator for 20 min. Cell plates were placed in the CellKey, a baseline was established for 5 min, 15 µL of agonist was added, and responses were collected over 15 min.
GTPγ γ S assays
GTPγS binding assays were performed in a scintillation proximity assay (SPA) 96-well (G i PCR X) or 384-well (M4) format. Assay buffer (pH 7.4) contained 20 mM HEPES, 10 mM MgCl 2 , 100 mM NaCl, 30 µM guanosine diphosphate (GDP), and 200 pM GTPγ 35 S. To this buffer was added 0.1% bovine serum albumin (BSA; G i PCR X assay) or 1 mM DTT and 5 mM EDTA (M4 assay). Polyvinyltoluene-wheat germ agglutinin (PVT-WGA) SPA beads (GE Healthcare RPNQ0001, Piscataway, NJ) and plasma membranes were added at 50 µg/well and 10 µg/well, respectively, for G i PCR X or 100 µg/well and 5 µg/well, respectively, for M4. Diluted test compounds were added to achieve a final assay concentration of 0.1% DMSO. For antagonist assays, an EC 80 of agonist was included. After mixing for 1.5 h, plates were centrifuged at 1000 rpm for 10 min and counted on a TopCount scintillation counter using a quench program specific for the assay.
cAMP assay
Cells from an adherent culture at 60% to 80% confluence were harvested in nonenzymatic dissociation buffer, diluted in cAMP assay buffer (Dulbecco's phosphate-buffered saline), centrifuged, and resuspended in assay buffer containing 300 µM RO20-1724 (Tocris Biosciences, Ellisville, MO), a phosphodiesterase inhibitor. In total, 22,500 cells/well (15 µL) in 384-well plates were exposed to test compounds in the presence of 30 µM forskolin for 30 to 40 min at room temperature (RT) in the 45-µL reaction mixture. To terminate the reaction, cells were lysed in detergent buffer (15 µL/well) provided in the CatchPoint™ cAMP Fluorescent Assay Kit (Molecular Devices Corporation, Sunnyvale, CA). With this immunoassay kit, the amount of cAMP in lysate samples (10-20 µL) was determined on a GeminiXS fluorescent plate reader (Molecular Devices Corporation) equipped with SoftMaxPro software.
Quantifying G i -Coupled GPCR Activity with CDS
Data analysis
Unless noted, CellKey data reflect the maximum change in extracellular impedance (dZiec). Concentration response curves were generated by fitting data to a 4-parameter logistic equation using Prism 4.0 software (GraphPad, San Diego, CA) or the XLfit plugin (IDBS, Bridgewater, NJ) for MS Excel. All data variability is presented as standard deviation. Pearson correlation tests were performed to assess covariance between data sets. The resulting correlation coefficient, r, is indicated in each figure legend. Each of the correlations was statistically significant (p < 0.01).
The typical variability observed in a particular assay (95% confidence interval) is defined by 2 times the average standard error of pEC 50 (or pIC 50 ) values obtained with > 12 test compounds. A variability of 3 (linear scale) means that EC 50 values of subsequently tested compounds would be expected to fall within 3-fold of their average EC 50 95% of the time. The resulting value from this analysis is called the assay variability value.
RESULTS
G i PCR assay development and validation
The dopamine D 2S receptor is a G i -coupled receptor activated endogenously by dopamine. In CellKey assays using CHO cells overexpressing D 2S , dopamine increased impedance in a timeand concentration-dependent manner (Fig. 1A) . This increase in impedance (dZiec) is consistent with the prototypical response for G i PCRs. 1 The D 2S assay did not require special plating conditions or media; the magnitude of the signal was dependent on cell density (Fig. 1B) . Untransfected CHO cells did not show a dopamine-induced increase in impedance (Fig. 1B) . The D 2selective antagonists raclopride and risperidone did not give a response alone but did block the dopamine signal ( Fig. 1B and data not shown), providing an additional measure of specificity. Assay variance was judged using an EC 80 (4 nM) of dopamine and buffer control, yielding a Z´ value of 0.53, which reflects a robust assay. 7 The maximum dopamine-induced impedance change was consistent within an experiment (across 3 plates) but varied between experiments on different days (dZiec 78 ± 5.3, 74 ± 4.7, and 53 ± 5.0 ohms), perhaps due to plating conditions. Despite the variation in maximal impedance change, the resulting potencies were highly similar for all 3 experiments (dopamine pEC 50 = 9.0 ± 0.1). Thus, as is the case with most functional assays, comparing maximal responses across multiple experiments requires data to be normalized to percent of control.
Synthetic D 2 receptor agonists were evaluated in the CellKey assay, including the partial agonists aripiprazole 8 and S(-)-3-PPP. 8, 9 Each compound induced a concentration-dependent increase in dZiec; the maximal response for both aripiprazole and S(-)-3-PPP was less than that for dopamine, as expected (Fig. 1C) . D 2S agonist potency and efficacy was also quantified using cAMP levels as the functional readout. For 5 of the 6 agonists, the EC 50 value obtained in CellKey was within 4-fold of the EC 50 value obtained in the cAMP assay ( Table 1) , indicating good agreement between the 2 functional assays. The differing results with bromocryptine reflect weaker than anticipated potency in the cAMP assay compared to literature values. 9 The variability seen with these 6 compounds in the CellKey assay was similar to that observed in the cAMP assay ( Table 1) . Overall, there was a strong positive correlation for both potency and efficacy of D 2 agonists between the 2 assays. The straightforward assay development observed for D 2S was essentially duplicated with another G i PCR, arbitrarily named G i PCR X. One nuance in the G i PCR X assay development was related to media conditions. Cells plated in media containing standard FBS gave a statistically significant response to the natural agonist (termed agonist X) but only ~4 ohms greater than control. Plating cells in media containing either dialyzed FBS or serum-free media increased this response to ~20 ohms above control. Pretreating the cells with endogenous agonist for 30 min reversed the enhancement seen with dialyzed serum. These data are consistent with the expected presence of the endogenous agonist in serum and raise the possibility that CellKey can detect activation-dependent down-regulation. Further studies would be needed to assess this possibility.
Under these optimized assay conditions, the natural agonist (termed agonist X) gave an EC 50 = 0.23 ± 0.07 nM. This value was ~20-fold more potent than the value obtained in GTPγS binding (5.6 0 ± 1.07 nM). The CellKey assay yielded a Zv alue of 0.63 when using an agonist EC 80 .
Agonists: dynamic range and SAR comparison
In order for CellKey to support agonist drug discovery, its dynamic range must be sufficient to reliably detect changes in efficacy and support progression of SAR over at least 1000fold enhancements in potency. As shown in Figure 1B , the CellKey provided high precision data for D 2 receptor agonists spanning ~100-fold potency range. To further test the dynamic range of CellKey assays, we selected 15 structurally diverse G i PCR X partial agonists varying in efficacy from 20% to 80% and in potency from 0.25 to 630 nM in GTPγS binding.
CellKey-generated concentration response curves showed equivalent precision for compounds across the entire range of both potency and efficacy ( Fig. 2A,B) . The assay variability value (defined in Methods) for this agonist CellKey assay is 1.9. Hence, the EC 50 values of test compounds should fall within 1.9-fold of their average EC 50 95% of the time. In comparison, the assay variability value for the agonist GTPγS assay is 3.3. The pEC 50 values obtained in CellKey and GTPγS showed strong positive correlation. The dynamic range was compressed from 1000-fold in GTPγS to 100-fold in CellKey, which suggests that GTPγS may have a wider capacity to differentiate EC 50 values. The E max values obtained in CellKey correlated well with GTPγS data (Fig. 2C) .
Quantifying antagonists
To test CellKey for the necessary dynamic range in antagonist mode, 13 structurally diverse G i PCR X antagonists were selected spanning a 500-fold range in potency in the GTPγS binding assay. CellKey-generated concentration response curves showed equivalent precision for compounds across the range of IC 50 values ( Fig. 3) . Comparison of CellKey-generated pIC 50 values with GTPγS data revealed a strong positive correlation and similar dynamic range (Fig. 3B) . The assay variability values were comparable: 1.5 for CellKey and 2.6 for GTPγS.
Because color quenching is a significant problem with some detection systems, several colored compounds also were tested to determine if any would appear as false-positive antagonists in the assay. Dyes FD&C yellow 5, FD&C red 40, FD&C blue 1, and FD&C red 3 were tested and showed no detectable response alone, nor did they quench the response to agonists.
Detecting endogenous receptors
Agonist X does not stimulate GTPγS binding in membranes from parental CHO cells which suggests that G i PCR X is not expressed in these cells or is expressed at a level below that which can be detected by GTPγS binding. However, in the CellKey assay using parental CHO cells, a weak response was sometimes observed with agonist X. When detected, the response was ≤ 10% of the signal seen in G i PCR X-transfected CHO cells. Different cell culture and assay conditions were evaluated to determine if a stronger agonist X response could be reliably observed in parental CHO cells. Changing cell plating density and different cell culture media did not augment the signal. However, in the presence of dialyzed FBS (Hyclone, Logan, UT), agonist X consistently elicited a G i -coupled increase in impedance with sufficient magnitude and precision to enable pharmacological studies.
The EC 50 for agonist X in the modified CellKey assay was 2 nM (data not shown). This is 10-fold weaker than that observed in G i PCR X overexpressed cells (Fig. 2) and is consistent with reports showing that reduced agonist potency can be a consequence of reducing GPCR density. [10] [11] [12] Although not sufficient to prove that the response to agonist X in parental CHO cells was indeed mediated by G i PCR X, we characterized the response with the set of G i PCR X antagonists (Fig. 4A) .
The rank-order potency for inhibiting this response paralleled that observed in the G i PCR X overexpressed cells (Fig. 4B) .
The assay variability value for antagonists was 2.5, demonstrating that CellKey can provide high-quality SAR data under conditions of low receptor expression in which GTPγS binding is not sensitive enough to detect an agonist response. 
Quantifying positive allosteric modulators
In recent years, many pharmaceutical companies have used functional assays to screen for compounds that positively or negatively modulate GPCRs via allosteric mechanisms. We evaluated the ability of CellKey to quantify known positive allosteric modulators (PAMs) of the M4 muscarinic receptor and compared these results to data generated with GTPγS binding. Modulator activity is defined by both potency and efficacy (or cooperativity) values. Modulator potency (EC 50 ) represents the concentration of test compound that produces a half-maximal response to a low concentration of agonist (typically an agonist EC 20 ). Cooperativity represents the maximum shift in the agonist concentration response curve caused by the modulator.
M4-expressing CHO cells produced a robust CellKey response to agonist alone (acetylcholine EC 50 = 40 nM), yielding a Z´ of 0.70. The agonist response was completely inhibited with the muscarinic antagonists scopolamine (IC 50 = 1.0 nM) and pirenzapine (IC 50 = 59 nM). In comparison, the 384-well GTPγS binding assay yielded an acetylcholine EC 50 of 384 nM and a Z´ of 0.50 (data not shown). Known M4 PAMs enhanced the agonist response in CellKey, as demonstrated by a leftward shift in the agonist concentration response curve (Fig. 5A) . The 3 PAMs showed a similar rank order in cooperativity values using CellKey and GTPγS, although the magnitude of each value was slightly larger in CellKey ( Table 2 ) which indicates greater dynamic range.
In CellKey, each of the 3 PAMs caused concentration-dependent enhancement of the response to an agonist EC 20 (Fig. 5B) . AZ202 and thiochrome gave pEC 50 values of 5.8 and 4.6, respectively, whereas the effect with brucine oxide was too small to yield an accurate pEC 50 value ( Table 2 ). In the GTPγS assay, the effects of all 3 compounds were smaller; a pEC 50 value could only be determined for AZ202. AZ202, thiochrome, and brucine oxide gave maximal agonist responses of 40%, 15%, and 10%, respectively, in the GTPγS assay compared to 95%, 80%, and 20% in CellKey. The pEC 50 value for AZ202 in the GTPγS assay (6.3) was similar to that observed in CellKey (5.8) . Thus, CellKey can be used to quantify both potent and weakly efficacious M4 PAMs with superior performance compared to GTPγS binding.
DISCUSSION
To support drug discovery SAR studies, new assay technologies must meet high standards for assay signal window, dynamic range, and reproducibility. New CDS-based instruments developed in configurations suitable for whole-cell GPCR assays represent promising but untested technology for secondary screening applications-hence the experiments described in this report. The time required to optimize assay conditions for screening against the D 2S , G i PCR X, and muscarinic M4 receptors was 3 to 4 weeks for each target, similar to that required for GTPγS and cAMP-based assays. Each of the CellKey assays demonstrated a Z´ value that reflects a robust assay. In addition, interassay variability of compound potency values was acceptable in each of the assays described in this report, with a 3-fold difference in potency values being statistically significant. This level of precision is suitable to support SAR studies and is usually achieved with G i PCR functional assays. In addition to assay reproducibility, translation of SAR information across different assay systems that use the same target preparation is critical. For this reason, the G i PCR X agonist EC 50 values and antagonist IC 50 values generated with CellKey were compared to results from GTPγS binding assays. The assessment was made more challenging by using partial agonists, compounds that have less than a fully efficacious response and therefore a smaller signal window in which to quantify potency. Nonetheless, a positive correlation was observed in both agonist EC 50 and antagonist IC 50 values from the 2 assays (Figs. 2B, 3B) . Taken together, the similarities in relative rank-order potency and precision suggest that CellKey can be used instead of or in combination with GTPγS for advancing SAR.
In comparing absolute values, agonists tended to be modestly more potent and efficacious in CellKey versus GTPγS binding. G i PCR X antagonists also appeared slightly more potent in CellKey than in GTPγS binding (Fig. 3) . This may reflect more efficient receptor-effector coupling in the wholecell CellKey assay or perhaps greater signal amplification in CellKey compared to the receptor-proximal measurement of GTPγS binding. Future studies would be needed to compare CellKey with reporter assays where cellular pathway amplification is known to occur.
CellKey measurements have been generated from both endogenous receptors on primary cells and cell lines, 6, 13 which suggests that the technology may be sensitive enough to provide pharmacological information under conditions of low receptor density, a more physiological condition than that observed with recombinant overexpressed targets. Under standard assay conditions, agonist X gave variable results on parental CHO cells, ranging from no detectable signal to 10% of that seen with overexpressed G i PCR X cells. By evaluating multiple buffer conditions, a consistent and increased agonist response was obtained. This is in contrast to GTPγS binding, which was not sensitive enough to detect an agonist response using plasma membranes from these cells. Concentration response curves for a set of 15 antagonists showed good precision across a wide IC 50 range and correlated with potency data obtained in receptor overexpressing cells (Fig. 4C) . This CellKey study demonstrated (1) the ability to detect endogenous response, (2) suitable sensitivity and dynamic range on endogenous receptors to provide antagonist SAR data (but requiring optimization of assay conditions), and (3) the need for potent and selective tool compounds to characterize the response because of the difficulty attributing an endogenous response to a particular receptor. Although additional studies are required to attribute the pharmacology to G i PCR X, these results demonstrate the feasibility of quantifying receptor activation and inhibition under low expression conditions.
There has been increasing interest in the search for positive allosteric modulators of GPCRs to overcome potential liabilities of synthetic agonists (e.g., desensitization due to chronic activation and limited selectivity within a GPCR family). Positive modulators that lack intrinsic agonist activity can enhance the biologic response to endogenous agonist (i.e., use-dependent amplification). As shown in Figure 5 , positive allosteric modulators of the M4 muscarinic receptor can be quantified using CDS, with sensitivity and precision that is equivalent to or better than GTPγS binding ( Table 2 ). The limited number of known M4 modulators prevents a thorough profiling of this class of pharmacological tools. However, the ability to quantify activity of receptor modulators in intact cells is a particular advantage compared to a membrane preparation, where the loss of ionic gradients and intracellular factors that can influence GPCR function may affect the pharmacological profile of receptor modulators. In summary, CDS technology provided suitable precision and dynamic range with G i PCR agonists, antagonists, and PAMs to enable SAR studies. The time required to develop and optimize assay conditions is similar to other detection systems commonly used to quantify GPCR responses. The throughput is roughly equivalent to other 96-well functional assays used in secondary screening: a 6-plate assay can be completed within 2.5 h. Because CDS can also quantify agonist and antagonist responses to GPCRs that couple to G s and G q transduction pathways, this detection system represents a versatile platform to quantify GPCR functional activity for secondary screening activities, including mechanistic pharmacology studies.
